Praxis Precision Medicines Announces Positive Results from the EMBRAVE Part A Trial of Elsunersen in Patients with SCN2A Early-Onset Developmental and Epileptic Encephalopathy

Data ReadoutpositiveElsunersenPositive

AI Analysis

Summary

Praxis Precision Medicines announced positive Part A trial results for Elsunersen in SCN2A Early-Onset Developmental and Epileptic Encephalopathy patients, achieving a statistically significant 77% placebo-adjusted seizure reduction from baseline (p=0.015).

Clinical Trial Data

Phase

Part A

Primary Endpoint

Met

Outcome Details

Elsunersen demonstrated placebo-adjusted seizure reduction from baseline of 77% (p=0.015)

Importance:7/10

Sentiment:

0.85

rare_diseaseepilepsyclinical_trial_dataseizure_reduction

Related Companies

$PRAX

Read the original article

Published by GlobeNewswire Clinical Studies on April 6, 2026 12:00 PM

Read Original